There is no panel matching the key "Alert"
There is no panel matching the key "MicroAlert"

Cancer & Blood Disorders Clinical Trials

Gundersen Health System has about 100 research studies available for cancer patients at any given time.

With support from Gundersen Medical Foundation, the Cancer and Blood Disorders Center offers research studies through participation in regional and national cancer treatment cooperative groups. By sharing clinical research efforts and measuring collective results, treatments are advanced more rapidly than any institution can accomplish alone. Participation in these groups can shorten the time it takes for us to get new, more effective drugs on the market.

Sometimes patients are concerned that if they don't get the experimental therapy, they will only get a placebo. However, in cancer research, the patient will either get the standard treatment or the new experimental drug that has shown signs to be potentially better than the standard treatment. Not everyone will qualify for a cancer research study, but for those who do, it can offer new hope.

Brain/Central Nervous System Cancer

  • Alliance A221101: Armodafinil in Reducing Cancer-Related Fatigue in Patients With Glioblastoma Multiforme
  • Alliance A071401: Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations (Suspended)
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NCCTG N0577: Phase III Randomized Study of Radiotherapy Alone Versus Radiotherapy With Concurrent and Adjuvant Temozolomide Versus Temozolomide Alone in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Glioma
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection

Breast Cancer

EARLY STAGE

Adjuvant

  • Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL)
  • A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
  • A221505: Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
  • ECOG E1Z11: Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Female Patients With Stage I-III Breast Cancer (Caucasian/Other races cohort closed to accrual 2/24/2014)
  • NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
  • NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
  • PALLAS (AFT-05/PrE0109): PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (Stage IIa stratum closed as of 8/15/2017)
  • SWOG S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
  • URCC-16070: Refractory Nausea

  • WF-97116: A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

Neoadjuvant

  • Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
  • ECOG EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
  • URCC-16070: Refractory Nausea

ADVANCED/METASTATIC

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification

  • SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Gastrointestinal Cancer

COLORECTAL

  • A021502: Randomized Trial of Standard Chemotherapy
    Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
  • EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
  • EAQ162CD: Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-GI004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1417CD: Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer
  • SWOG S1609:(Suspended 4/20/18) "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
  • URCC-16092: Phase II Study of Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy

HEPATOCELLULAR

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

GASTRIC

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

ESOPHAGEAL

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

PANCREATIC

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

CHOLANGIOCARCINOMA

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Genitourinary Cancer

BLADDER

  • A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation

  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1602: A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

PROSTATE

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • RTOG 0924: Phase III Randomized Study of Androgen-Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Patients With Unfavorable Intermediate- or Favorable High-Risk Prostate Cancer
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1602: A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer (SUSPENDED)
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

RENAL CELL

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Gynecological Cancer

CERVICAL

  • GOG 0263: Phase III Randomized Study of Adjuvant Radiation Versus Chemoradiation Therapy in Patients With Intermediate-Risk Stage I-IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • RTOG 0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiotherapy With Versus Without Adjuvant Chemotherapy in Patients With High-Risk Early-Stage Cervical Carcinoma After Radical Hysterectomy
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

ENDOMETRIAL

  • GOG 0238: Phase II Randomized Study of Pelvic Radiotherapy With Versus Without Cisplatin in Patients With Recurrent Endometrial Cancer
  • Lunchbox: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel for Optimally Debulked Advanced Endometrial Carcinoma
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) (SUSPENDED 6/16/2017)
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Head and Neck Cancer

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-HN001: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
  • NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin SUSPENDED 06/25/2018
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • RTOG 1216: Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer SUSPENDED 02/22/2016
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Leukemia

ACUTE LEUKEMIA

ALL

  • ECOG E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

AML

  • Connect® MDS/AML Disease Registry (Celgene NCI-2015-01815)
  • ECOG E2906: Phase III Randomized Study of Clofarabine Versus Daunorubicin Hydrochloride and Cytarabine Followed by Decitabine Versus Observation in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (Suspended 02/23/2015)
  • ECOG-ACRIN EA9131: Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
  • SWOG S1612: A Randomized Phase II/III Trial of "Novel Therapeutics" Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older (LEAP: Less-Intense AML Platform Trial) (Suspended)

CHRONIC LEUKEMIA

  • No studies available at this time

Lung Cancer

NON-SMALL CELL

  • Alliance A081105: Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
  • Alliance A151216: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (ALCHEMIST Treatment Trial)
  • EA5152: A Randomized Phase II Trial of Nivolumab,
    Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients with Previously Treated Non-Squamous NSCLC (SUSPENDED)
  • ECOG E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
  • EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers(An ALCHEMIST Treatment Trial)
  • MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-LU002: Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

SMALL CELL

  • CALGB 30610: Phase III Randomized Study of Three Different Thoracic Radiotherapy Regimens in Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

MESOTHELIOMA

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Lymphoma

HODGKIN'S

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection

NON-HODGKIN'S

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PrECOG PrE0403: Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma as Front Line Therapy
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1608: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Melanoma

  • ECOG EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab +Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib +Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
  • ECOG EA6141: Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma (SUSPENDED 6/23/2017)
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • PUMA-NER-5201: An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
  • STRATA (STR-001): Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
  • SWOG S1320: A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib and Trametinib in BRAF V066E/K Mutant Melanoma
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • SWOG S1616: A Phase II Randomized Study of Nivolumab
    (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1Agent.

Multiple Myeloma

  • Alliance A061202: Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
  • Alliance A061402: Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy
  • ECOG E1A11: Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Myelodysplastic Syndrome

Pediatric Oncology

For more information regarding our pediatric trials, please contact:

Nancy Fisher
(608)775-2733
nrfisher@gundersenhealth.org

Prevention/Symptom Management

  • DCP-001: Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
  • GLNE010: Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma (Temporarily Closed to Accrual)
  • URCC – 13059: A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults

  • WF-30917CD: A Stepped-Care Telehealth Approach To Treat Distress In Rural Cancer Survivors

Sarcoma

  • No trials currently available.

Screenings

  • WF-20817CD: Implementation of Smoking Cessation Services within NCI NCORP Community Sites with Organized Lung Cancer Screening Programs

If you are interested in getting additional information on a research study, please contact:

Lori Meyer, RN, OCN, CCRC
(608) 775-2579 or (800) 362-9567, ext. 52579
lameyer@gundersenhealth.org

Kathy Frisby, BSN, RN, OCN
(608) 775-6631 or (800) 362-9567, ext. 56631
kafrisby@gundersenhealth.org

Love + Medicine

Every day, Gundersen Health System staff deliver great medicine plus a little something extra—we call it Love + Medicine.

Share Your Story